Registered number
11304280
Transpharm Clinical Consulting Ltd
Unaudited Filleted Accounts
30 April 2025
Transpharm Clinical Consulting Ltd
Registered number: 11304280
Balance Sheet
as at 30 April 2025
Notes 2025 2024
£ £
Fixed assets
Tangible assets 3 752 1,503
Current assets
Debtors 4 8,951 725
Cash at bank and in hand 162,717 122,413
171,668 123,138
Creditors: amounts falling due within one year 5 (12,676) (6,009)
Net current assets 158,992 117,129
Total assets less current liabilities 159,744 118,632
Provisions for liabilities (143) (286)
Net assets 159,601 118,346
Capital and reserves
Called up share capital 1 1
Profit and loss account 159,600 118,345
Shareholder's funds 159,601 118,346
The director is satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.
The member has not required the company to obtain an audit in accordance with section 476 of the Act.
The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
The accounts have been prepared and delivered in accordance with the special provisions applicable to companies subject to the small companies regime. The profit and loss account has not been delivered to the Registrar of Companies.
Dr M. Taylor
Director
Approved by the board on 17 June 2025
Transpharm Clinical Consulting Ltd
Notes to the Accounts
for the year ended 30 April 2025
1 Accounting policies
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Turnover
Turnover is measured at the fair value of the consideration received or receivable, net of discounts.
Tangible fixed assets
Tangible fixed assets are measured at cost less accumulative depreciation and any accumulative impairment losses. Depreciation is provided on all tangible fixed assets, other than freehold land, at rates calculated to write off the cost, less estimated residual value, of each asset evenly over its expected useful life, as follows:
Fixtures, fittings, tools and equipment over 3 years
Debtors
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts.
Creditors
Short term creditors are measured at transaction price (which is usually the invoice price).
Taxation
A current tax liability is recognised for the tax payable on the taxable profit of the current and past periods. Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Current and deferred tax liabilities are not discounted.
2 Employees 2025 2024
Number Number
Average number of persons employed by the company 0 0
3 Tangible fixed assets
Plant and machinery etc
£
Cost
At 1 May 2024 2,255
At 30 April 2025 2,255
Depreciation
At 1 May 2024 752
Charge for the year 751
At 30 April 2025 1,503
Net book value
At 30 April 2025 752
At 30 April 2024 1,503
4 Debtors 2025 2024
£ £
Trade debtors 8,860 600
Other debtors 91 125
8,951 725
5 Creditors: amounts falling due within one year 2025 2024
£ £
Taxation and social security costs 9,992 4,759
Other creditors 2,684 1,250
12,676 6,009
6 Other information
Transpharm Clinical Consulting Ltd is a private company limited by shares and incorporated in England. Its registered office is:
International House
Cornhill
London
EC3V 3NG
Transpharm Clinical Consulting Ltd 11304280 false 2024-05-01 2025-04-30 2025-04-30 VT Final Accounts April 2025 Dr M. Taylor No description of principal activity 11304280 2023-05-01 2024-04-30 11304280 core:WithinOneYear 2024-04-30 11304280 core:ShareCapital 2024-04-30 11304280 core:RetainedEarningsAccumulatedLosses 2024-04-30 11304280 2024-05-01 2025-04-30 11304280 bus:PrivateLimitedCompanyLtd 2024-05-01 2025-04-30 11304280 bus:AuditExemptWithAccountantsReport 2024-05-01 2025-04-30 11304280 bus:Director40 2024-05-01 2025-04-30 11304280 1 2024-05-01 2025-04-30 11304280 2 2024-05-01 2025-04-30 11304280 core:PlantMachinery 2024-05-01 2025-04-30 11304280 countries:England 2024-05-01 2025-04-30 11304280 bus:FRS102 2024-05-01 2025-04-30 11304280 bus:FilletedAccounts 2024-05-01 2025-04-30 11304280 2025-04-30 11304280 core:WithinOneYear 2025-04-30 11304280 core:ShareCapital 2025-04-30 11304280 core:RetainedEarningsAccumulatedLosses 2025-04-30 11304280 core:PlantMachinery 2025-04-30 11304280 2024-04-30 11304280 core:PlantMachinery 2024-04-30 iso4217:GBP xbrli:pure